Evidence map›Paper›PMID 41265004›Full record

ArticleVaccine2026

Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants.

Ninaad Lasrado, Annika Rössler, Isabella McConnell, Katherine Molloy, Ritobhas Bhowmik, Christine Happle, Ruoran Guan, Katherine McMahan, Juliana Pereira, Jinyan Liu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ninaad LasradoBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Annika RösslerBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Isabella McConnellBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Katherine MolloyBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ritobhas BhowmikBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Christine HappleGerman Centre for Lung Research (DZL), Hannover BREATH, Hannover, Germany; German Centre for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany; Department for Paediatric Pneumology, Hannover Medical School, Hannover, Germany; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Ruoran GuanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Katherine McMahanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Juliana PereiraBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jinyan LiuBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Erica BorducchiBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Liping WangBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Krishna ShahBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Bridget WixtedBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Metodi V StankovGerman Centre for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Alexandra Dopfer-JablonkaGerman Centre for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany; Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Ai-Ris Y CollierBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Georg M N BehrensGerman Centre for Lung Research (DZL), Hannover BREATH, Hannover, Germany; German Centre for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany.
Dan H BarouchBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dbarouch@bidmc.harvard.edu.

Funding

Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
NCI NIH HHS U01 CA260476
6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to evolve five years after the initial outbreak. Although mRNA vaccines encoding the JN.1 and KP.2 Spike proteins were authorized in fall 2024, it remains unclear whether vaccine updates will be necessary for variants containing antigenically closely related Spike proteins. In this study, we evaluated the immunogenicity of JN.1 and KP.2 mRNA boosters in participants from Germany and the United States, respectively. Both vaccines induced robust and similar neutralizing antibody responses against JN.1, KP.2, and other globally relevant variants such as LP.8.1.1 and NB.1.8.1. These data suggest that updating the vaccine formulation to closely related strains will likely offer only modest additional benefits against currently circulating variants.

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2AdultAntibodies, NeutralizingAntibodies, ViralFemaleGermanyHumansMaleMiddle AgedmRNA VaccinesSpike Glycoprotein, CoronavirusUnited StatesVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticBoosterCOVID-19JN.1KP.2mRNA

Identifiers

PMID41265004
PMCPMC12643176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.